Sponsor

Syndeio Biosciences, Inc

Clinical research sponsor

Published trials8
Recruiting shown3
Roles2
SourceClinicalTrials.gov

Clinical trials

8 shown
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderNCT07115329 · lead sponsor · 2026-01-05
RECRUITING
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderNCT06547489 · lead sponsor · 2025-02-03
RECRUITING
Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy VolunteersNCT05597241 · lead sponsor · 2022-10-15
COMPLETED
Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human VolunteersNCT04618263 · lead sponsor · 2020-10-26
TERMINATED
Zelquistinel in the Treatment of Adults With Major Depressive DisorderNCT03726658 · lead sponsor · 2018-11-08
COMPLETED
Zelquistinel in the Treatment of Major Depressive DisorderNCT03586427 · lead sponsor · 2018-06-13
COMPLETED
Safety and Tolerability of Zelquistinel in Normal Human VolunteersNCT04981561 · lead sponsor · 2016-12-09
COMPLETED
Apimostinel + Automated Neurocognitive Training for DepressionNCT06400121 · collaborator · 2024-10-28
RECRUITING

Sponsor roles

lead sponsor7
collaborator1

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.